Lloyd A Gall

Array ( [id] => 16885431 [patent_doc_number] => 20210171626 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 Modulators [patent_app_type] => utility [patent_app_number] => 17/104344 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17669 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17104344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16686695 [patent_doc_number] => 20210069170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH [patent_app_type] => utility [patent_app_number] => 16/951012 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18117569 [patent_doc_number] => 11548950 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-10 [patent_title] => Agent, uses and methods for treatment [patent_app_type] => utility [patent_app_number] => 17/097457 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 42 [patent_no_of_words] => 30051 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17097457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16825689 [patent_doc_number] => 20210140982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => IDENTIFICATION OF SPATIAL BIOMARKERS OF BRAIN DISORDERS AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/073242 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58904 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17073242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16854919 [patent_doc_number] => 20210155664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => REGENERATING FUNCTIONAL NEURONS FOR TREATMENT OF NEUROLOGICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/072946 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26510 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17072946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16614972 [patent_doc_number] => 20210033625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS [patent_app_type] => utility [patent_app_number] => 17/068403 [patent_app_country] => US [patent_app_date] => 2020-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17068403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16728992 [patent_doc_number] => 20210096139 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => TAU KINETIC MEASUREMENTS [patent_app_type] => utility [patent_app_number] => 17/033047 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15415 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 165 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17033047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16748872 [patent_doc_number] => 20210100881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => METHODS FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE [patent_app_type] => utility [patent_app_number] => 17/025241 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16929 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17025241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18172707 [patent_doc_number] => 11572404 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-07 [patent_title] => Humanized anti-Tau(pS422) antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 17/023963 [patent_app_country] => US [patent_app_date] => 2020-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 16 [patent_no_of_words] => 40173 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17023963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16914030 [patent_doc_number] => 20210187122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => MESSENGER RNA THERAPY FOR THE TREATMENT OF FRIEDREICH'S ATAXIA [patent_app_type] => utility [patent_app_number] => 17/016860 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21704 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17016860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711949 [patent_doc_number] => 20210079096 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => B7-H4 ANTIBODIES AND METHODS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/006670 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25031 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17006670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16512968 [patent_doc_number] => 20200392226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => ENZYMATIC MODIFICATION OF ANTI-AQP4 AUTOANTIBODY FOR MODULATING NEUROMYELITIS OPTICA [patent_app_type] => utility [patent_app_number] => 17/003153 [patent_app_country] => US [patent_app_date] => 2020-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13408 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17003153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16482367 [patent_doc_number] => 20200375967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => COMPOSITIONS OF PSILOCYBIN AND ANALOGS [patent_app_type] => utility [patent_app_number] => 16/992631 [patent_app_country] => US [patent_app_date] => 2020-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5452 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16992631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16466794 [patent_doc_number] => 20200368331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals [patent_app_type] => utility [patent_app_number] => 16/987831 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16987831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18369138 [patent_doc_number] => 11649292 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Compositions and methods for treating and preventing inflammation [patent_app_type] => utility [patent_app_number] => 16/983185 [patent_app_country] => US [patent_app_date] => 2020-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 86 [patent_figures_cnt] => 149 [patent_no_of_words] => 29657 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16983185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16435734 [patent_doc_number] => 20200353059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => TPP-1 Formulations and Methods for Treating CLN2 Disease [patent_app_type] => utility [patent_app_number] => 16/941454 [patent_app_country] => US [patent_app_date] => 2020-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16941454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398770 [patent_doc_number] => 20200339628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES [patent_app_type] => utility [patent_app_number] => 16/929994 [patent_app_country] => US [patent_app_date] => 2020-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16929994 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16576629 [patent_doc_number] => 20210011030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => BLOCKADE OF TIM-1 PATHWAYS and P-SELECTIN PATHWAYS IN TREATMENT OF NEUROINFLAMMATORY DEGENERATIVE DISEASE [patent_app_type] => utility [patent_app_number] => 16/917330 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14925 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16917330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506206 [patent_doc_number] => 20200385462 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => ANTIBODY FOR USE IN DETECTING EARLY-STAGE DAMAGE OF BLOOD BRAIN BARRIER DURING CEREBRAL ISCHEMIC STROKE AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/910058 [patent_app_country] => US [patent_app_date] => 2020-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4031 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16910058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16582871 [patent_doc_number] => 20210017273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => ANTIBODY FOR DETECTING EARLY DAMAGE OF BLOOD-BRAIN BARRIER IN ISCHEMIC STROKE AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/907296 [patent_app_country] => US [patent_app_date] => 2020-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4090 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16907296 [rel_patent_id] =>[rel_patent_doc_number] =>)